COVID-19 restrictions impact the global supply chain: DEMECAN imports medicinal cannabis from the Netherlands to ensure supply.

DEMECAN Standort Nauenhof

Berlin/Dresden, 06. May 2020 – The German medicinal drug market is currently experiencing exceptional circumstances due to the global COVID-19 pandemic. Supply chain disruptions around the world have affected pharmaceutical imports to Germany, including medical cannabis imports. For example, many Canadian products are currently severely backordered. DEMECAN – the German specialist for medicinal cannabis – helps by importing medicinal cannabis from Bedrocan from the Netherlands to ensure a consistent supply for German pharmacies.

Even prior to the pandemic, in 2019 there were increasing cannabis supply shortages in Germany. The pandemic has encouraged DEMECAN to close supply gaps locally. To that end, last year the Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN a contract to produce and process medicinal cannabis for Germany. DEMECAN is currently constructing the manufacturing facility near Dresden. In addition, the DEMECAN wholesale department started the import of medicinal cannabis and is expanding its distribution network.

Dr. Cornelius Maurer, Co-founder and Managing Director of DEMECAN explains: “The current restrictions concerning the corona pandemic make it clear that Germany has to close supply chain gaps and provide its citizens with consistent access to medicinal cannabis. We are looking forward to cultivating our own medicinal cannabis in Germany soon and are glad to be able to provide Bedrocan cannabis to German pharmacies in the meantime. It is our goal to help patients in this hard time.”

DEMECAN is the only Germany company that covers all manufacturing steps for medical cannabis – including cultivation, processing, storage and delivering to pharmacies. Dr. Adrian Fischer, Dr. Cornelius Maurer und Dr. Constantin von der Groeben founded DEMECAN in 2017 with the goal of giving patients the access to medicinal cannabis with “Made in Germany” quality. In May 2019 the BfArM awarded DEMECAN a government contract to produce and process medicinal cannabis in Germany. The production and processing of medicinal cannabis will follow the highest pharmaceutical standards. In addition to its German cultivation operations, DEMECAN operates as a cannabis wholesaler and works together with cannabis producers all over the world to import medicinal cannabis that meet the highest pharmaceutical standards. The DEMECAN group has its headquarters in Berlin and is a member of the “Verband der Cannabis versorgenden Apotheken e.V.”

Further information:
Press contact:

Download (en)
Download (de)

Weitere Presse­mitteilungen